NO994481D0 - Sammensetninger og fremgangsmÕter for redusering av okulær hypertensjon - Google Patents

Sammensetninger og fremgangsmÕter for redusering av okulær hypertensjon

Info

Publication number
NO994481D0
NO994481D0 NO994481A NO994481A NO994481D0 NO 994481 D0 NO994481 D0 NO 994481D0 NO 994481 A NO994481 A NO 994481A NO 994481 A NO994481 A NO 994481A NO 994481 D0 NO994481 D0 NO 994481D0
Authority
NO
Norway
Prior art keywords
compositions
methods
ocular hypertension
reducing ocular
reducing
Prior art date
Application number
NO994481A
Other languages
English (en)
Other versions
NO994481L (no
NO327713B1 (no
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994481(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO994481D0 publication Critical patent/NO994481D0/no
Publication of NO994481L publication Critical patent/NO994481L/no
Publication of NO327713B1 publication Critical patent/NO327713B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
NO19994481A 1997-03-17 1999-09-16 Sammensetninger for reduksjon av okulaer hypertensjon og anvendelse av sammensetning NO327713B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17
PCT/EP1998/001483 WO1998041208A1 (en) 1997-03-17 1998-03-13 Compositions and methods for reducing ocular hypertension

Publications (3)

Publication Number Publication Date
NO994481D0 true NO994481D0 (no) 1999-09-16
NO994481L NO994481L (no) 1999-09-16
NO327713B1 NO327713B1 (no) 2009-09-14

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994481A NO327713B1 (no) 1997-03-17 1999-09-16 Sammensetninger for reduksjon av okulaer hypertensjon og anvendelse av sammensetning

Country Status (33)

Country Link
EP (1) EP0969846B2 (no)
JP (2) JP4920124B2 (no)
KR (1) KR100555818B1 (no)
CN (1) CN1236775C (no)
AR (2) AR002194A1 (no)
AT (1) ATE257385T1 (no)
AU (1) AU738781B2 (no)
BR (2) BR9808016A (no)
CA (1) CA2280089C (no)
CL (1) CL2009001870A1 (no)
CO (1) CO4940427A1 (no)
CY (1) CY2526B1 (no)
CZ (1) CZ299833B6 (no)
DE (1) DE69820997T3 (no)
DK (1) DK0969846T4 (no)
EE (1) EE04091B1 (no)
ES (1) ES2214706T5 (no)
HK (1) HK1026841A1 (no)
HU (1) HU228896B1 (no)
ID (1) ID22389A (no)
IL (1) IL131041A0 (no)
MY (1) MY122237A (no)
NO (1) NO327713B1 (no)
NZ (1) NZ337322A (no)
PE (1) PE61899A1 (no)
PL (1) PL197509B1 (no)
PT (1) PT969846E (no)
RU (1) RU2197970C2 (no)
SI (1) SI0969846T2 (no)
TW (1) TW527187B (no)
UA (1) UA63938C2 (no)
WO (1) WO1998041208A1 (no)
ZA (1) ZA982188B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) * 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
CA2558135C (en) * 2004-03-18 2012-08-14 R-Tech Ueno, Ltd. Aqueous composition comprising thiazole derivative
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
ES2460967T3 (es) * 2005-08-02 2014-05-16 Santen Pharmaceutical Co., Ltd. Método para la prevención de la degradación de una sustancia térmicamente inestable
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
KR101382922B1 (ko) * 2006-03-13 2014-04-08 가부시키가이샤 아루떼꾸 우에노 수성 조성물
JP5275214B2 (ja) * 2006-03-17 2013-08-28 ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド 酸化に不安定な成分を含む眼科用安定組成物
KR20090082401A (ko) * 2006-10-31 2009-07-30 알콘 리서치, 리미티드 안 질환 치료용 ｐａｉ－１ 결합 조절제
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
CA2702082A1 (en) * 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
CN101959500A (zh) * 2008-03-17 2011-01-26 爱尔康研究有限公司 包含硼酸类化合物-多元醇络合物的水性药物组合物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
WO2012141334A1 (en) * 2011-04-12 2012-10-18 R-Tech Ueno, Ltd. Aqueous ophthalmic composition
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9314528B2 (en) 2011-12-07 2016-04-19 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
MX2017006474A (es) 2014-11-25 2017-09-12 Allergan Inc Composiciones oftalmicas estabilizadas de omega 3.
US11752175B2 (en) * 2018-09-21 2023-09-12 Cornell University Compositions and methods for glaucoma
AU2020272127B2 (en) 2019-04-12 2022-12-08 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458587B1 (en) * 1990-05-22 1993-07-14 R-Tech Ueno Ltd. Synergistic combination for ophthalmic use
WO1992013836A1 (en) * 1991-02-07 1992-08-20 Allergan, Inc. 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
JP2742333B2 (ja) * 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
RU2197970C2 (ru) 2003-02-10
CY2526B1 (en) 2006-02-08
JP2001515502A (ja) 2001-09-18
SI0969846T2 (sl) 2010-12-31
CO4940427A1 (es) 2000-07-24
DE69820997T2 (de) 2004-12-09
HUP0002194A2 (hu) 2000-12-28
HUP0002194A3 (en) 2012-08-28
EP0969846B2 (en) 2010-08-25
AR011192A1 (es) 2000-08-02
WO1998041208A1 (en) 1998-09-24
ATE257385T1 (de) 2004-01-15
DE69820997D1 (de) 2004-02-12
NZ337322A (en) 2001-05-25
BR9808016A (pt) 2000-03-08
AU7035398A (en) 1998-10-12
CN1249687A (zh) 2000-04-05
ZA982188B (en) 1998-09-17
PE61899A1 (es) 1999-06-30
CL2009001870A1 (es) 2010-01-22
EE9900410A (et) 2000-04-17
ES2214706T5 (es) 2011-02-02
EP0969846A1 (en) 2000-01-12
HU228896B1 (en) 2013-06-28
CA2280089C (en) 2009-03-03
NO994481L (no) 1999-09-16
PL335168A1 (en) 2000-04-10
ES2214706T3 (es) 2004-09-16
DE69820997T3 (de) 2011-10-06
DK0969846T3 (da) 2004-04-13
PT969846E (pt) 2004-05-31
DK0969846T4 (da) 2010-12-20
UA63938C2 (uk) 2004-02-16
AR002194A1 (es) 1998-01-07
ID22389A (id) 1999-10-07
EP0969846B1 (en) 2004-01-07
CN1236775C (zh) 2006-01-18
PL197509B1 (pl) 2008-04-30
BRPI9816218B1 (pt) 2016-04-12
IL131041A0 (en) 2001-01-28
AU738781B2 (en) 2001-09-27
JP4920124B2 (ja) 2012-04-18
CZ299833B6 (cs) 2008-12-10
CA2280089A1 (en) 1998-09-24
MY122237A (en) 2006-04-29
JP2010043110A (ja) 2010-02-25
KR20000076330A (ko) 2000-12-26
TW527187B (en) 2003-04-11
KR100555818B1 (ko) 2006-03-03
NO327713B1 (no) 2009-09-14
SI0969846T1 (en) 2004-06-30
EE04091B1 (et) 2003-08-15
HK1026841A1 (en) 2000-12-29
CZ325799A3 (cs) 2000-01-12

Similar Documents

Publication Publication Date Title
NO994481D0 (no) Sammensetninger og fremgangsmÕter for redusering av okulær hypertensjon
NO20003096D0 (no) Sammensetninger og fremgangsmÕter for behandling av ADD
DE69637691D1 (de) Azeotropähnliche zusammensetzungen und ihre verwendung
NO991676D0 (no) FremgangsmÕter og sammensetninger for immunmodulering
DE69729947T2 (de) N-substituierte 2-cyanopyrrolidine
DE69726189D1 (de) Mikrokeratom
DK0991658T3 (da) Dolastatin 15-derivater
ATE209959T1 (de) Mikroverkapselte zusammensetzungen
ATE293672T1 (de) Farbschonende zusammensetzungen
DE69709610T2 (de) Kupfer-Nickel-Beryllium Legierung
DE69924489D1 (de) Getreide-beta-glukanzusammensetzungen und verfahren
DE69620914D1 (de) Perfluoralkoxycycloalkancarbonylfluorid-zusammensetzungen und ihre verwendung
ID16838A (id) Komposisi dekafluoropentana
DE59708683D1 (de) Kupfer-Chrom-Titan-Silizium-Legierung und ihre Verwendung
ID17419A (id) Komposisi dekafluoropentana
DE29619310U1 (de) Pinzette
DE29616065U1 (de) Pinzette
DE29722501U1 (de) Ausgleichsbacke
NO20000038D0 (no) Benzodiazepinderivater og tilsvarende anvendelse og sammensetning
BR1100398A (pt) Composição oftalmológica
DK1133300T3 (da) Desmethylolanzapinsammensætninger og fremgangsmåder
SE9603301D0 (sv) Compounds and compositions
BR9602545A (pt) Microcerátomo
FI2773U1 (fi) Laituri
NO962586D0 (no) Miljö-ovn

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees